Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis

John J. Engemann, Joëlle Y. Friedman, Shelby D. Reed, Robert I. Griffiths, Lynda A. Szczech, Keith S. Kaye, Martin E. Stryjewski, L. Barth Reller, Kevin A. Schulman, G. Ralph Corey, Vance G. Fowler

Research output: Contribution to journalArticlepeer-review

116 Scopus citations

Abstract

OBJECTIVE: To examine the clinical outcomes and costs associated with Staphylococcus aureus bacteremia among hemodialysis-dependent patients. DESIGN: Prospectively identified cohort study. SETTING: A tertiary-care university medical center in North Carolina. PATIENTS: Two hundred ten hemodialysis- dependent adults with end-stage renal disease hospitalized with S. aureus bacteremia. RESULTS: The majority of the patients (117; 55.7%) underwent dialysis via tunneled catheters, and 29.5% (62) underwent dialysis via synthetic arteriovenous fistulas. Vascular access was the suspected source of bacteremia in 185 patients (88.1%). Complications occurred in 31.0% (65), and the overall 12-week mortality rate was 19.0% (40). The mean cost of treating S. aureus bacteremia, including readmissions and outpatient costs, was $24,034 per episode. The mean initial hospitalization cost was significantly greater for patients with complicated versus uncomplicated S. aureus bacteremia ($32,462 vs $17,011; P = .002). CONCLUSION: Interventions to decrease the rate of S. aureus bacteremia are needed in this high-risk, hemodialysis-dependent population.

Original languageEnglish (US)
Pages (from-to)534-539
Number of pages6
JournalInfection control and hospital epidemiology
Volume26
Issue number6
DOIs
StatePublished - Jun 1 2005

ASJC Scopus subject areas

  • Epidemiology
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis'. Together they form a unique fingerprint.

Cite this